Dr Reddy introduces Testosterone gel

Dr. Reddy's Laboratories informed the bourses that it has launched Testosterone Gel 1.62 per cent, a therapeutic equivalent generic version of AndroGel (testosterone gel) 1.62 per cent, approved by USFDA.

As per IQVIA, the said gel has a projected market size of US$815.6 million for the most recent twelve months ending in February 2019

Looking at the recently concluded quarter Q3FY19, the revenue increased by 1 per cent on YoY basis and PAT jumped by 45 per cent on YoY basis. The company’s Q3FY19 sales mix comprises of North America (39 per cent), Europe (5 per cent), India (18 per cent), Emerging markets (20 per cent), PSAI (15 per cent) and Proprietary Products & Others (3 per cent).

Dr. Reddy’s Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.

On Monday, the stock of Dr. Reddy's Laboratories opened at Rs. 2,887.60 and made an intraday high of Rs. 2,926.20 on the BSE. At 12:50 hours, the stock was trading at nearly Rs. 2,910.85 on the BSE.